EGFR and head and neck squamous cell carcinoma: To examine the possibility of clinical application of iTAP, we used an anti-epidermal growth factor receptor (EGFR) antibody immunotoxin (IT-cetuximab, IT-Cmab) that targets EGFR, which is widely used for the treatment of HNSCC.